ClinicalTrials.gov
public full text
Public Domain
A Study of Apabetalone in Subjects With Long -COVID
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PREDICT: A PBRN Feasibility Study on COVID-19 Screening in Dental Practice#808011
- Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)#1044765
- Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial#1259764
- DISulfiram for COvid-19 (DISCO) Trial#801592
- Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)#1307935
Record · ID 1397404
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive